These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 27762512

  • 1. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial.
    Goyal O, Sidhu SS, Sehgal N, Puri S.
    J Assoc Physicians India; 2016 Sep; 64(9):30-35. PubMed ID: 27762512
    [Abstract] [Full Text] [Related]

  • 2. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
    Sharma P, Kumar A, Shrama BC, Sarin SK.
    Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
    [Abstract] [Full Text] [Related]

  • 3. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
    Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, Sharma N, Bhalla A, Chawla YK, Singh V.
    Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
    [Abstract] [Full Text] [Related]

  • 4. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC, REVERSE Study Investigators.
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [Abstract] [Full Text] [Related]

  • 5. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.
    Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, Sharma AK, Choudhary NS, Chawla Y, Nain CK.
    J Hepatol; 2012 Jun; 56(6):1293-8. PubMed ID: 22322237
    [Abstract] [Full Text] [Related]

  • 6. Terlipressin therapy for renal failure in cirrhosis.
    Triantos CK, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli L, Leandro G, Patch D, Burroughs AK.
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
    [Abstract] [Full Text] [Related]

  • 7. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
    Muñoz LE, Alcalá EG, Cordero P, Martínez MA, Vázquez NY, Galindo S, Mendoza E, Segura JJ.
    Ann Hepatol; 2009 Apr; 8(3):207-11. PubMed ID: 19841499
    [Abstract] [Full Text] [Related]

  • 8. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
    Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A.
    J Hepatol; 2007 Oct; 47(4):499-505. PubMed ID: 17560680
    [Abstract] [Full Text] [Related]

  • 9. Noradrenaline or terlipressin for hepatorenal syndrome?
    Celis P, Rada G.
    Medwave; 2015 Aug 27; 15 Suppl 2():e6235. PubMed ID: 26334297
    [Abstract] [Full Text] [Related]

  • 10. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study.
    Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA.
    Indian J Gastroenterol; 2018 Sep 27; 37(5):424-429. PubMed ID: 30178092
    [Abstract] [Full Text] [Related]

  • 11. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
    Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, Vargas HE, Reddy KR, Pappas SC, Teuber P, Escalante S, Jamil K.
    Aliment Pharmacol Ther; 2017 Jun 27; 45(11):1390-1402. PubMed ID: 28370090
    [Abstract] [Full Text] [Related]

  • 12. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
    Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK.
    J Gastroenterol Hepatol; 2003 Feb 27; 18(2):152-6. PubMed ID: 12542598
    [Abstract] [Full Text] [Related]

  • 13. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
    Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R.
    J Gastroenterol Hepatol; 2002 Aug 27; 17(8):882-8. PubMed ID: 12164964
    [Abstract] [Full Text] [Related]

  • 14. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
    Wong F, Pappas SC, Boyer TD, Sanyal AJ, Bajaj JS, Escalante S, Jamil K, REVERSE Investigators.
    Clin Gastroenterol Hepatol; 2017 Feb 27; 15(2):266-272.e1. PubMed ID: 27464593
    [Abstract] [Full Text] [Related]

  • 15. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
    Sagi SV, Mittal S, Kasturi KS, Sood GK.
    J Gastroenterol Hepatol; 2010 May 27; 25(5):880-5. PubMed ID: 20074149
    [Abstract] [Full Text] [Related]

  • 16. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation.
    Mattos ÂZ, Mattos AA, Ribeiro RA.
    Eur J Gastroenterol Hepatol; 2016 Mar 27; 28(3):345-51. PubMed ID: 26649801
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of terlipressin and albumin vs. noradrenaline and albumin in adult patients with hepatorenal syndrome: A systematic review and meta-analysis.
    Malik A, Malik MI, Qureshi S, Nadir A.
    Ann Hepatol; 2024 Mar 27; 29(4):101495. PubMed ID: 38460713
    [Abstract] [Full Text] [Related]

  • 18. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
    Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P.
    Dig Dis Sci; 2008 Mar 27; 53(3):830-5. PubMed ID: 17939047
    [Abstract] [Full Text] [Related]

  • 19. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.
    Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J.
    J Hepatol; 2000 Jul 27; 33(1):43-8. PubMed ID: 10905585
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
    Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, Uemura M, Fukui H, Sumino Y, Matsuzaki Y, Masaki N, Kokubu S, Okita K.
    J Gastroenterol; 2012 Mar 27; 47(3):313-20. PubMed ID: 22038555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.